Dec. 9, 2004 -- The U.S. Food and Drug Administration (FDA) and Ortho Biotech Products warned healthcare professionals via letter of important information regarding the safe dosing of epoetin alfa ...
Patients had a diagnosis of nonmyeloid malignancy with ≥ 8 weeks of planned chemotherapy, age ≥ 18 years, and anemia (hemoglobin ≤ 11 g/dL). Patients were randomly assigned 1:1 to DA 200 μg every two ...
To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate ...
Among over 300 patients who required red blood cell transfusions for anemia, 58.5% of those who received luspatercept achieved transfusion independence with hemoglobin increase versus 31.2% of those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results